title: Prompt response to rituximab of severe hemolytic anemia with both cold and warm autoantibodies.
abstract: A 71-year-old male with severe autoimmune hemolysis with both cold agglutinins and warm antibodies was intolerant of prednisone and cyclophosphamide. Rituximab was given during a 60-day period when he required 41 units of packed cells to maintain hemoglobin above 75 g/l. Two weeks later hemoglobin stabilized at 95 g/l, and further transfusions were not required. A second course of rituximab was given 4 months later for continued hemolysis. A satisfactory hemoglobin was maintained for 9 months from initial treatment, when hemoglobin again fell to 65 g/L. A prompt response to a third course of rituximab was obtained. This is the second patient with both cold agglutinins and warm antibodies with severe hemolytic anemia who has had a prompt response to rituximab. This treatment should be considered when a rapid response is needed or when a patient has failed to respond to more standard therapies.
authors.affiliation: Department of Medicine, University of Alberta and University of Alberta Hospital, Edmonton, Alberta, Canada.
authors.forename: Duncan
authors.initials: D
authors.lastname: Webster
authors.forename: Bruce
authors.initials: B
authors.lastname: Ritchie
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Mant
mesh_terms: D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies / Q000276:immunology*; D006801:Humans; D008297:Male; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D000069283:Rituximab